SVB Leerink Comments on Marinus Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:MRNS)
SVB Leerink Comments on Marinus Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:MRNS)
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Rating) – Investment analysts at SVB Leerink cut their FY2023 earnings estimates for shares of Marinus Pharmaceuticals in a report issued on Monday, January 23rd. SVB Leerink analyst M. Goodman now expects that the biopharmaceutical company will post earnings per share of ($3.25) for the year, down from their prior forecast of ($2.90). SVB Leerink has a "Outperform" rating and a $23.00 price objective on the stock. The consensus estimate for Marinus Pharmaceuticals' current full-year earnings is ($2.88) per share. SVB Leerink also issued estimates for Marinus Pharmaceuticals' FY2024 earnings at ($2.50) EPS, FY2025 earnings at ($1.50) EPS and FY2026 earnings at $1.10 EPS.
Marinus製藥公司(納斯達克代碼:MRNS-GET Rating)-SVB Leerink的投資分析師在1月23日(星期一)發佈的一份報告中下調了Marinus製藥公司2023財年的收益預期。SVB Leerink分析師M.Goodman現在預計,這家生物製藥公司今年的每股收益將為3.25美元,低於此前預測的2.90美元。SVB Leerink對該股的評級為“跑贏大盤”,目標價為23.00美元。對Marinus PharmPharmticals目前全年收益的普遍估計為每股2.88美元。SVB Leerink還發布了對Marinus PharmPharmticals 2024財年每股收益(2.50美元)、2025財年每股收益(1.50美元)和2026財年每股收益1.10美元的預期。
Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) last released its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of $0.25 by ($0.60). Marinus Pharmaceuticals had a negative return on equity of 244.60% and a negative net margin of 77.96%. The business had revenue of $2.34 million during the quarter, compared to analysts' expectations of $28.56 million.
馬瑞納斯製藥公司(納斯達克代碼:MRNS-GET Rating)最近一次公佈財報是在11月7日(星期一)。這家生物製藥公司公佈本季度每股收益(0.35美元),低於分析師普遍預期的0.25美元(0.60美元)。Marinus製藥公司的淨資產回報率為負244.60%,淨利潤率為負77.96%。該業務當季營收為234萬美元,高於分析師預期的2,856萬美元。
Marinus Pharmaceuticals Trading Up 4.6 %
Marinus製藥公司股價上漲4.6%
MRNS opened at $5.96 on Wednesday. The company has a debt-to-equity ratio of 0.91, a current ratio of 8.41 and a quick ratio of 8.40. The company's 50 day simple moving average is $4.47 and its two-hundred day simple moving average is $5.47. Marinus Pharmaceuticals has a 1-year low of $3.46 and a 1-year high of $12.37. The firm has a market capitalization of $221.69 million, a price-to-earnings ratio of -12.96 and a beta of 1.10.
週三,MRNS開盤報5.96美元。該公司的債務權益比為0.91,流動比率為8.41,速動比率為8.40。該公司的50日簡單移動均線切入位為4.47美元,200日簡單移動均線切入位為5.47美元。Marinus PharmPharmticals的一年低點為3.46美元,一年高位為12.37美元。該公司的市值為2.2169億美元,市盈率為-12.96倍,貝塔係數為1.10。
Institutional Trading of Marinus Pharmaceuticals
Marinus製藥公司的制度性交易
Institutional investors have recently added to or reduced their stakes in the stock. Amalgamated Bank acquired a new stake in Marinus Pharmaceuticals in the 1st quarter valued at approximately $56,000. Renaissance Technologies LLC acquired a new stake in Marinus Pharmaceuticals in the 1st quarter valued at approximately $317,000. Virtu Financial LLC acquired a new stake in Marinus Pharmaceuticals in the 1st quarter valued at approximately $221,000. MetLife Investment Management LLC increased its holdings in Marinus Pharmaceuticals by 63.8% in the 1st quarter. MetLife Investment Management LLC now owns 20,363 shares of the biopharmaceutical company's stock valued at $190,000 after purchasing an additional 7,928 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Marinus Pharmaceuticals by 39.5% in the second quarter. Price T Rowe Associates Inc. MD now owns 15,600 shares of the biopharmaceutical company's stock worth $76,000 after acquiring an additional 4,417 shares in the last quarter. Institutional investors and hedge funds own 86.88% of the company's stock.
機構投資者最近增持或減持了該股。合併銀行在第一季度收購了Marinus製藥公司的新股份,價值約5.6萬美元。復興技術公司在第一季度收購了Marinus製藥公司的新股份,價值約31.7萬美元。Virtu Financial LLC在第一季度收購了Marinus製藥公司的新股份,價值約為221,000美元。大都會人壽投資管理有限責任公司第一季增持Marinus PharmPharmticals股份63.8%。大都會人壽投資管理有限責任公司現在擁有20,363股這家生物製藥公司的股票,價值19萬美元,在上個季度又購買了7928股。最後,Price T Rowe Associates Inc.MD在第二季度持有的Marinus PharmPharmticals股份增加了39.5%。Price T Rowe Associates Inc.MD現在擁有15,600股這家生物製藥公司的股票,價值76,000美元,此前在上個季度又購買了4,417股。機構投資者和對衝基金持有該公司86.88%的股票。
Marinus Pharmaceuticals Company Profile
Marinus製藥公司簡介
(Get Rating)
(獲取評級)
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Marinus製藥公司是一家制藥公司,專注於為患有罕見遺傳性癲癇和其他癲癇障礙的患者開發和商業化產品。它提供ZTALMY,一種口服混懸劑,用於治療與急性和慢性護理中的成人和兒童患者羣體以及住院和自我給藥環境中的細胞週期蛋白依賴性激酶樣缺乏症相關的癲癇發作。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Marinus Pharmaceuticals (MRNS)
- AMD Is Still One Of The Best Semiconductor Stocks Out There
- Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- 免費獲取StockNews.com關於Marinus製藥的研究報告(MRNS)
- AMD仍是市面上最好的半導體股票之一
- 兩大股利大王:強生還是雅培?
- 網絡安全類股已經見底了嗎?
- 聯合太平洋,諾福克南方進入購買區
- 柔順治療公司的差距增加了34%:未來還會有更多的好處嗎?
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Marinus PharmPharmticals Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Marinus製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。